Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension

Mizuki Momoi; Takahiro Hiraide; Yoshiki Shinya; Hiromi Momota; Shogo Fukui; Michiyuki Kawakami; Keiichi Fukuda; Masaharu Kataoka

doi:10.1016/j.rmcr.2022.101592

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension

Respir Med Case Rep. 2022 Jan 30:36:101592. doi: 10.1016/j.rmcr.2022.101592. eCollection 2022.

Authors

Mizuki Momoi¹, Takahiro Hiraide¹, Yoshiki Shinya¹, Hiromi Momota¹, Shogo Fukui², Michiyuki Kawakami³, Keiichi Fukuda¹, Masaharu Kataoka^{1

4}

Affiliations

¹ Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
² Department of Rehabilitation, Keio University Hospital, Tokyo, Japan.
³ Department of Rehabilitation Medicine, Keio University School of Medicine, Tokyo, Japan.
⁴ Second Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.

Abstract

The effective therapy for pulmonary arterial hypertension (PAH) with inadequate clinical response is scarce except for lung transplantation when prostacyclin infusion is ineffective. The purpose of this study is to investigate the efficacy and safety of selexipag in addition to the infusion of prostacyclin. Nine patients [median 38 (36-49) years of age; 78% female] with PAH whose clinical response was inadequate despite the use of prostacyclin infusion analogs, were evaluated. Addition of selexipag significantly improved hemodynamics and no serious adverse events were observed. Selexipag with prostacyclin infusion analogs can be an effective therapeutic strategy for the PAH patients with inadequate clinical response.

Keywords: Drug combinations; Prostacyclin; Selexipag.

Publication types

Case Reports